Trakya University, Faculty of Medicine, Department of Obstetrics & Gynecology, Division of Perinatology, Edirne, Turkey.
Placenta. 2018 Feb;62:25-27. doi: 10.1016/j.placenta.2017.12.015. Epub 2017 Dec 18.
To investigate the levels of Prokineticin-1 (PROK1) and matrix metalloproteinase-2 (MMP-2) in second-trimester amniotic fluid (AF). AF samples were investigated in 81 patients. AF-PROK1 and AF-MMP-2 were not significantly associated with adverse pregnancy outcomes (preeclampsia, intrauterine growth retardation, spontaneous preterm birth, gestational diabetes, gestational hypertension). AF-PROK1 levels in patients with abnormal first-trimester screening were significantly higher than those who underwent amniocentesis due to abnormal second-trimester screening tests (p = .04). AF-PROK1 or AF-MMP-2 do not have a role in the prediction of adverse pregnancy outcomes.
检测妊娠中期羊水中的 Prokineticin-1（PROK1）和基质金属蛋白酶-2（MMP-2）水平。研究了 81 例患者的羊水样本。羊水-PROK1 和羊水-MMP-2 与不良妊娠结局（子痫前期、宫内生长受限、自发性早产、妊娠期糖尿病、妊娠期高血压）无显著相关性。因异常的中孕期筛查而接受羊膜穿刺术的患者的羊水-PROK1 水平显著高于因异常的早孕期筛查而接受羊膜穿刺术的患者（p=0.04）。羊水-PROK1 或羊水-MMP-2 不能用于预测不良妊娠结局。
